Sense Diagnostics

Executive Summary

Sense Neuro Diagnostics is developing a non-invasive, rapid diagnostic platform using multi-antenna radio frequency scanning to detect and differentiate acute neurological conditions such as stroke and traumatic brain injury within seconds. The device is designed for pre-hospital military field triage, emergency medical services, and continuous hospital monitoring, addressing critical time-to-treatment challenges in neurology. The company's core technology leverages low-energy RF waves to characterize brain tissue, offering a portable, radiation-free alternative to CT/MRI. While still in development with no disclosed funding or FDA approvals, the platform has the potential to significantly improve outcomes in stroke and TBI by enabling earlier, more accessible diagnosis outside traditional hospital settings. The market need is substantial: stroke is a leading cause of disability, and rapid differentiation between ischemic and hemorrhagic subtypes is critical for appropriate treatment. Sense Diagnostics' approach could reduce delays in emergency care and expand access in underserved or remote areas. However, the company faces regulatory and technical hurdles, including clinical validation and manufacturing scale-up. If successful, the device could also be used for continuous monitoring of neurological status in ICU settings. Given the early stage, the conviction score is moderate, reflecting the technology's promise balanced against execution risk.

Upcoming Catalysts (preview)

• Q3 2026Initial results from military field trial40% success
• Q4 2026FDA 510(k) submission for stroke detection30% success
• Q2 2026Strategic partnership with emergency medical services provider50% success